Ionis Pharmaceuticals (NQ: IONS )
52.78
USD
+1.51
(+2.95%)
Official Closing Price
Updated: 4:29 PM EST, Mar 5, 2021
Add to My Watchlist
Press releases about Ionis Pharmaceuticals
Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis
March 01, 2021
From PR Newswire
Ionis reports fourth quarter and full year 2020 financial results and recent business achievements
February 24, 2021
From PR Newswire
Ionis to present at upcoming investor conferences
February 19, 2021
From PR Newswire
Ionis to hold 2020 financial results webcast
February 11, 2021
From PR Newswire
Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
January 07, 2021
From PR Newswire
Ionis to present at 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021
From PR Newswire
Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation
December 17, 2020
From PR Newswire
Ionis highlights achievements, commercial strategy and technology advancements at Investor Day
December 08, 2020
From PR Newswire
Red Clover Market Size, Share, Price, Trends, Growth, Analysis, Key Players, Outlook, Report, Forecast 2020-2025 | ExpertMarketResearch.com
December 04, 2020
From iCrowdNewswire
Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conference
December 02, 2020
From PR Newswire
Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome
December 01, 2020
From PR Newswire
Ionis to hold virtual investor day event
December 01, 2020
From PR Newswire
Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol
November 30, 2020
From PR Newswire
Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development
November 23, 2020
From PR Newswire
Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020
November 13, 2020
From PR Newswire
Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association (AHA) Scientific Sessions 2020
November 12, 2020
From PR Newswire
Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference
November 10, 2020
From PR Newswire
Ionis to present at upcoming virtual investor conferences
November 09, 2020
From PR Newswire
Ionis reports third quarter 2020 financial results and recent business achievements
November 04, 2020
From PR Newswire
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
November 03, 2020
From PR Newswire
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product
October 30, 2020
From PR Newswire
Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trial
October 22, 2020
From PR Newswire
Ionis to hold third quarter 2020 financial results webcast
October 21, 2020
From PR Newswire
Ionis antisense medicine being evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil
October 15, 2020
From PR Newswire
/C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./
October 13, 2020
From PR Newswire
Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis
October 13, 2020
From PR Newswire
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
October 12, 2020
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.